NCHR Testimony regarding Front-of-Package Nutrition Information Labeling

July 15, 2025: NCHR submitted written comments to the U.S. Food and Drug Administration in support of the proposed rule on front-of-package nutrition labeling, recommending stronger, clearer labeling requirements, especially for young children. They suggested additional testing to ensure consumers understand and benefit from the labels, including those with limited literacy or English proficiency.

Read More »

FDA Panel to Revisit Menopausal Hormone Therapy

Politico describes the FDA panel on the risks and benefits of hormone therapy for menopause: breast cancer, heart disease,stroke, dementia. Zuckerman points out that the panel is one-sided, ignoring data on risks and not allowing public comments from patients or experts to ask questions or describe studies indicating cancer and other serious risks.

Read More »

MIT Technology Review: Meet Jim O’Neill, the longevity enthusiast who is now RFK Jr.’s right-hand man

MIT Technology Review July 1, 2025: HHS Deputy Secretary Jim O’Neill wants unproven medical treatments to be very widely available and HHS to focus funding on longevity research so that those who can afford them can live much longer. This could include areas at sea or in states that are not subject to FDA safeguards. What will happen to the millions of Americans who need healthcare for diseases they already have?

Read More »

NCHR Comments on AHRQ’s Mindfulness-Based Interventions for Mental Health and Wellbeing in Children and Adolescents

The following written comment was submitted by the Health Policy Director, Dr. Amanda Berhaupt at The National Center for Health Research’ (NCHR)  to the Agency of Health Research and Quality (AHRQ). AHRQ requested comments on the protocol for the Mindfulness-Based Interventions (MBI) for Mental Health and Wellbeing in Children and Adolescents: A Systematic Review by […]

Read More »